New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza
Executive Summary
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.
You may also be interested in...
AZ's Lynparza Shines Again In Prostate Cancer Study
With a PDUFA date fast approaching, AstraZeneca has presented more data from the PROfound study, this time showing that Lynparza improved OS compared to hormonal therapies in men with advanced castration-resistant prostate cancer with BRCA1/2 or ATM mutations.
Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer
Lynparza will weather the failure of the Phase III GY004 study, but VEGF inhibitor Recentin’s future looks even less certain; other studies of the combination continue.
Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports